<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000517</url>
  </required_header>
  <id_info>
    <org_study_id>LFX/V0.1</org_study_id>
    <nct_id>NCT03000517</nct_id>
  </id_info>
  <brief_title>PK of Levofloxacin in MDR-TB Patients</brief_title>
  <official_title>Pharmacokinetics of Levofloxacin in MDR-TB Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The emergence and spread of multi-drug resistant and extensively-drug resistant strains of&#xD;
      Mycobacterium tuberculosis (MDR/XDR-TB) have posed a great threat to global TB control and&#xD;
      elimination, limiting treatment success rate at worrisome 50% for MDR-TB. Among various&#xD;
      factors contributing to the development of drug resistance, low drug exposure is well&#xD;
      recognized. To overcome this, either new drugs have to be developed or the dose of currently&#xD;
      used therapy be optimized, or both. Fluoroquinolones (levofloxacin and moxifloxacin) and&#xD;
      aminoglycosides are important drugs in the MDR-TB treatment regimen. Development of acquired&#xD;
      drug resistance to these drugs could complicate and narrow down the available options, and&#xD;
      further exacerbate to pre-XDR and XDR-TB.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The main objective of this prospective clinical study is to understand the pharmacokinetics&#xD;
      of levofloxacin in MDR-TB patients, receiving standard dosage (750-1250mg) based on the body&#xD;
      weight and correlate drug exposure, with treatment outcomes.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A prospective pharmacokinetic study&#xD;
&#xD;
      Study population: 20 MDR-TB patients&#xD;
&#xD;
      Intervention: Patients receive once daily oral dosing of levofloxacin (750-1250mg) based on&#xD;
      the body weight, under MDR-TB treatment regimen of Nepal.&#xD;
&#xD;
      Main study parameters/end points:&#xD;
&#xD;
      The pharmacokinetic parameters(Vd, CL, AUC etc.) of levofloxacin are the primary end points&#xD;
      of the study. The Cmax/MIC and AUC0-24h/MIC ratios are the best predictive parameters for&#xD;
      efficacy of levofloxacin treatment and will be estimated. Pharmacokinetics will be evaluated&#xD;
      in plasma and in oral fluid&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2016</start_date>
  <completion_date type="Actual">January 24, 2018</completion_date>
  <primary_completion_date type="Actual">October 27, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Period I (15-30) day and Period II (45-60) day</time_frame>
    <description>The main objective of this prospective clinical trial is to evaluate the levofloxacin exposures (AUC) of a standard dose (750-1250mg) in plasma and saliva of MDR-TB patients.</description>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Multi-drug Resistant Tuberculosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and saliva samples of MDR-TB patients on 0 hr premedication and 1,2,4,8 hrs post&#xD;
      mediation.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with previously treated or newly diagnosed MDR-TB who are at the end of first&#xD;
        month(15-30th day) and second month (45-60th day) of their treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with TB, with Mycobacterium tuberculosis by culture/ Gene Xpert&#xD;
&#xD;
          -  Patient is 18 years or older with newly diagnosed or previously treated MDR-TB&#xD;
&#xD;
          -  Patient with sputum smear positive for acid-fast bacilli or sputum smear negative but&#xD;
             Gene Xpert (MTB/RIF) positive, and resistant to both isoniazid and rifampicin&#xD;
&#xD;
          -  Patients with MDR-TB receiving levofloxacin as a part of MDR-TB regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with neurologic or severe extra-pulmonary manifestations of tuberculosis&#xD;
&#xD;
          -  Pregnant women or breast feeding mothers with MDR-TB&#xD;
&#xD;
          -  Patients with diminished renal functions or on medications for the treatment of renal&#xD;
             disorders&#xD;
&#xD;
          -  Body weight &lt;35 kg&#xD;
&#xD;
          -  Patients treated with aluminium- and magnesium containing antacids and ferrous&#xD;
             sulphates, cimetidine and probenecid, theophylline, warfarin, zidovudine, digoxin or&#xD;
             cyclosporine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem Alffenaar</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen, University of Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Nepal Tuberculosis Project Clinic (GENETUP)</name>
      <address>
        <city>Kalimati</city>
        <state>Kathmandu</state>
        <zip>1494</zip>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>PhD PharmD Clinical Pharmacologist</investigator_title>
  </responsible_party>
  <keyword>levofloxacin</keyword>
  <keyword>multi-drug resistant TB</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

